Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management
- 1 May 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 7 (3), E53-E54
- https://doi.org/10.1093/ehjcvp/pvaa049
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infectionMedecine Et Maladies Infectieuses, 2020
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World PracticeBioMed Research International, 2018
- Inhibition of microglial activation with minocycline at the intrathecal level attenuates sympathoexcitatory and proarrhythmogenic changes in rats with chronic temporal lobe epilepsyNeuroscience, 2017
- Minocycline attenuates ischemia-induced ventricular arrhythmias in ratsEuropean Journal of Pharmacology, 2011
- Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrationsProceedings of the National Academy of Sciences of the United States of America, 2006
- Phagolysosomal Alkalinization and the Bactericidal Effect of Antibiotics: TheCoxiella burnetii ParadigmThe Journal of Infectious Diseases, 1992